RUNX2 and pancreatic neoplasm: In the present study, we have found that silencing of RUNX2 contributes to a significant enhancement of GEM sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells through the augmentation of TAp73-mediated cell death pathway.